Skip to main content

Want a detailed portfolio tracker?

Comparison Inhibikase Therapeutics (IKT) with Competitors

Inhibikase Therapeutics (IKT) industry is Biotechnology.

Free Cash Flow Yield
IKT-13.14%
Industry-1.75%
Upside-11.40%
P/E
IKT-4.01
Industry-20.52
Upside+1650.41%
P/S
IKT10.39
Industry10.01
Upside+3.76%
P/B
IKT1.62
Industry5.15
Upside-68.47%